Mizuho reiterates Sarepta stock rating after Novartis trial miss

Mizuho reiterated its Outperform rating and $31 price target on Sarepta after SRPT fell 10% to $20.35 following Novartis' failed Phase 3 HARBOR trial, arguing the sell-off is overdone because Sarepta's SRP-1003 has a differentiated delivery mechanism. Sarepta's Q2 2026 EPS of $0.64 beat the $0.22 consensus and revenue of $401.3M exceeded the $383M estimate, supported by cost controls and collaboration revenue. However, total sales declined sharply year over year amid weaker demand for Duchenne gene therapy ELEVIDYS, leaving the investment outlook mixed despite the analyst's bullish stance.

Analysis

The read-through to SRPT is less about target biology than about whether muscle-directed oligonucleotide delivery can produce durable, functionally meaningful benefit in a slowly progressive neuromuscular disease. A receptor-targeting differentiation thesis is plausible, but it remains a pre-clinical/clinical pharmacology question rather than evidence of superior efficacy; the market should not capitalize it until SRPT discloses exposure, splicing correction, durability and functional data. The more material valuation driver remains stabilization of the ELEVIDYS revenue base, where lower demand can pressure both the earnings multiple and cash runway despite near-term cost control.

The immediate selloff creates a tactical mean-reversion setup only if the decline was predominantly sympathy-driven rather than informed reassessment of SRPT's delivery platform. Over the next 1-3 months, investor focus should rotate to prescription trends, payer access, manufacturing capacity/utilization and management's full-year ELEVIDYS outlook; a guidance reduction would dominate any benefit from a favorable interpretation of a competitor's failure. Over 6-18 months, successful platform validation could expand SRPT's addressable neuromuscular pipeline, while another delivery-platform setback would raise the probability that the company is valued primarily on a challenged single-product franchise.

NVS has limited equity sensitivity to one neuromuscular program given its diversified earnings base; its more relevant second-order exposure is strategic rather than financial, as a failure may make externally sourced RNA-delivery assets cheaper. Consensus appears too quick to infer that a negative competitor study either invalidates all delivery approaches or validates SRPT's alternative mechanism. The correct conclusion is that the clinical bar for DM1 has risen: efficacy must translate into patient-relevant functional endpoints, not merely biomarker activity.

Key Decisions for Investors

• Tactical long SRPT only after confirming the post-event low holds for 2-3 sessions and no new ELEVIDYS demand or safety disclosure emerges; target a retracement of roughly half the event-driven drawdown over 1-3 months, with a hard exit on a break below the event low or any reduction to product-revenue guidance.
• Do not establish a fundamental 6-12 month SRPT overweight until diligence confirms quarterly ELEVIDYS prescriptions, payer approval rates, gross-to-net trends and cash burn. Those data—not the competitor study—determine whether current cost discipline can offset franchise de-risking.
• For biotech exposure, express the idiosyncratic view as long SRPT / short XBI in modest size rather than outright long beta; reassess if XBI weakness, higher real yields, or a broad risk-off tape explains more than half of SRPT's relative move.
• Avoid a directional NVS trade on this development. Monitor for licensing, acquisition, or pipeline reprioritization around RNA-delivery platforms over the next 6-18 months; such actions would be the investable confirmation that the trial outcome changed asset valuations.